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SUMMARY STATEMENT 
Oncofetal fibronectin expression positively correlates with the expression of TGF-β 
and TGF-β-related molecules in glioblastoma blood vessels. In endothelial cells TGF-
β induces oncofetal fibronectin, in turn modulating TGF-β superfamily signaling. 
 
ABSTRACT 
Gene splicing profiles are frequently altered in cancer, and the splice variants of 
fibronectin (FN) containing the extra-domains A (EDA) and B (EDB) referred to as 
EDA+FN and EDB+FN are highly up-regulated in tumor vasculature. TGF-β signaling 
has been attributed a pivotal role in glioblastoma, with TGF-β promoting 
angiogenesis and vessel remodeling. By immunohistochemical staining, we observed 
that the oncofetal FN isoforms EDA+FN and EDB+FN are expressed in glioblastoma 
vasculature. Ex vivo single cell gene expression profiling of patients’ tumors using the 
markers CD31 and alpha-smooth muscle actin (αSMA) respectively confirmed the 
predominant expression of FN, EDA+FN, and EDB+FN in the vascular compartment 
of glioblastoma. Specifically, within the CD31-positive cell population, we identified a 
trend of positive correlation in the expression of EDA+FN and EDB+FN with 
molecules associated with TGF-β signaling. Further, TGF-β induced EDA+FN and 
EDB+FN in human cerebral microvascular endothelial cells and glioblastoma-derived 
endothelial cells in a SMAD3/SMAD4-dependent manner. In turn, FN modulated 
TGF-β superfamily signaling in endothelial cells via the EDA and EDB domains, 
pointing towards a bidirectional influence between oncofetal FN and TGF-β 
superfamily signaling. 
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INTRODUCTION 
Fibronectins (FN) are high molecular mass adhesive glycoproteins of the extracellular 
matrix (ECM) involved in several processes including cell growth and differentiation, 
cell adhesion and migration (Hynes, 1990; Pankov and Yamada, 2002). FN is 
encoded by a single gene (Zardi et al., 1982), but various isoforms are generated by 
alternative splicing mechanisms and post-translational modifications (Schwarzbauer, 
1991). Three FN regions can be affected by alternative splicing: the extra-domain A 
(EDA), the extra-domain B (EDB) and the type III connecting sequence (IIICS) 
(Pankov and Yamada, 2002; Schwarzbauer, 1991). Specifically, the EDA and EDB 
domains may be included or excluded by exon usage or skipping (Pankov and 
Yamada, 2002). Both the EDA- and EDB-containing isoforms, EDA+FN and 
EDB+FN, preferentially appear in neo-vessels during embryogenesis and 
physiological angiogenesis as well as in pathological conditions including wound 
healing, atherosclerosis and tumorigenesis (Carnemolla et al., 1989; Castellani et al., 
1994; Ffrench-Constant et al., 1989; Rybak et al., 2007; Zardi et al., 1987). Therefore 
EDA+FN and EDB+FN are also termed oncofetal FN isoforms. EDB+FN is 
expressed around vasculature exclusively during neo-angiogenesis (Castellani et al., 
1994) so that antibodies specific for EDB+FN injected in tumor-bearing mice or 
cancer patients specifically accumulate in the tumor vasculature (Neri and Bicknell, 
2005; Santimaria et al., 2003). The EDB-specific antibody L19 is presently under 
investigation in clinical trials in cancer patients as one moiety of fusion proteins with 
cytokines such as interleukin-2 (NCT02957019) (Carnemolla et al., 2002; Zegers et 
al., 2015) or tumor necrosis factor (TNF)-α (NCT02076620) (Borsi et al., 2003; 
Danielli et al., 2015), or radio-labeled (Borsi et al., 2002; Erba et al., 2012; Poli et al., 
2013). 
Several genetic studies ascribed a fundamental role of FN in the morphogenesis and 
physiology of blood vessels (Astrof and Hynes, 2009). Transforming growth factor 
(TGF)-β superfamily members are fundamental regulators of endothelial cell 
physiology, too (Pardali and ten Dijke, 2009). The TGF-β superfamily consists of 33 
members, including the three TGF-β isoforms, TGF-β1, TGF-β2 and TGF-β3, and ten 
bone morphogenetic proteins (BMP). TGF-β superfamily signaling is triggered by the 
binding of TGF-β superfamily ligands to two functional classes of transmembrane 
receptors, known as type I, also known as the activin-like kinase (ALK), and type II 
receptors. Upon ligand binding, the type I/II TGF-β receptor heterocomplex is formed 
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and type I receptors, in turn, phosphorylate the receptor-regulated SMAD (R-SMAD) 
proteins. The phosphorylated R-SMAD together with the co-SMAD, SMAD4, 
translocate into the nucleus and modulate gene expression depending on the type 
and state of the cell (Massague, 2012). The type I receptors ALK4, ALK5 and ALK7 
phosphorylate SMAD2 and 3, whereas ALK1,2,3 and 6 phosphorylate SMAD1,5 and 
8. TGF-β signaling is commonly mediated by the ALK5/SMAD2/SMAD3 axis. 
However, in endothelial cells, TGF-β may also promote SMAD1,5,8 activation by the 
endothelium-specific receptor ALK1 (Goumans et al., 2002). Beyond, ALK5 has been 
shown to regulate SMAD1,5 signaling as well (Liu et al., 2009). Importantly, TGF-β 
responses also occur independently of SMAD through the activation of TGF-β-
dependent non-canonical signaling pathways including the phospho-inositide 3' 
kinase (PI3K)/Akt pathway (Zhang et al., 2013), the mitogen-activated protein kinase 
MAPK/ERK pathway, and the p38 and c-Jun N-terminal kinase (JNK) pathways 
(Moustakas and Heldin, 2005). 
Functional interactions between TGF-β and FN have been reported. TGF-β induces 
FN expression in different cell types (Ignotz and Massague, 1986). Also, TGF-β has 
been identified as one of the most important regulators of alternative splicing 
affecting the EDA and EDB of FN leading to an increase in EDA+FN and EDB+FN in 
several cell types (Balza et al., 1988; Borsi et al., 1990; Viedt et al., 1995). On the 
other hand, FN and its receptor integrin α5β1 positively regulate TGF-β- and BMP-
induced SMAD1,5,8 phosphorylation by promoting the formation of a complex of 
ALK1 and the TGF-β superfamily co-receptor endoglin in human microvascular 
endothelial cells (Tian et al., 2012). Beyond, in fibroblasts, a role for EDA+FN in 
influencing TGF-β activity has been suggested (Muro et al., 2008; Serini et al., 1998; 
White et al., 2008). 
TGF-β is a central regulator of the malignant phenotype of glioblastoma, the most 
common and aggressive malignant primary brain tumor of adults (Rodon et al., 2014; 
Wang et al., 2016). In glioblastoma, TGF- has a central role in both inducing 
angiogenesis and promoting vessel remodeling (Dieterich et al., 2012). FN is up-
regulated in glioblastoma vessels (Dieterich et al., 2012) with EDB+FN expression 
being abundant and positively correlating with tumor grade in gliomas (Castellani et 
al., 2002). Here we extend these investigations on FN in gliomas by investigating 
EDA+FN as well. We also aim at better understanding the interplay of glioma-derived 
oncogenic TGF- and oncofetal FN at the tumor-vasculature interface. 
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RESULTS 
 
Expression of EDA+FN and EDB+FN and of TGF-β signaling-associated 
molecules correlates in glioblastoma blood vessels. 
We first investigated the expression of total FN and of the EDA+FN and EDB+FN 
isoforms in ten human glioblastoma sections and also stained non-tumor human 
brain tissues derived from four patients with epilepsy as controls. We used the 
antibodies IST-5, reacting with a FN domain common to all FN isoforms, IST-9, 
reacting with the EDA domain, and C6, specific for EDB+FN (Fig. 1A). In all sections 
investigated, tumor-associated vessels, identified by staining serial sections for the 
endothelial cell marker CD31, showed high levels of FN, EDA+FN and EDB+FN, 
whereas the tumor tissue itself was negative for EDA+FN and EDB+FN and showed 
only low or very low levels of total FN (Fig. 1B, representative sections of two 
glioblastoma patients are shown). In all non-tumor tissues analyzed, blood vessels 
were strongly positive for total FN, but negative or weakly positive for EDA+FN and 
negative for EDB+FN (Fig. 1B, representative sections of one patient with epilepsy 
are shown). Accordingly, mRNA analysis of freshly dissociated glioblastoma samples 
divided into CD31+ and CD31- fractions showed that FN, EDA+FN, and EDB+FN 
were preferentially expressed in the CD31+ fraction containing the endothelial cells 
(Fig. 1C). Pericytes and vascular smooth muscle cells (VSMC) express alpha-smooth 
muscle actin (αSMA) and αSMA expression is restricted to the tumor blood vessels in 
glioblastoma (Fig. 1D). Given the vascular distribution of FN, EDA+FN and EDB+FN 
in glioblastoma we asked whether pericytes/VSMC may also be involved in FN 
expression in glioblastoma. We therefore aimed at a more detailed expression 
analysis performing single cell real-time polymerase chain reaction (scRT-PCR) of 
FN, EDA+FN and EDB+FN and of CD31 and αSMA as markers of the endothelial 
and pericytic/VSMC cells respectively in cells derived from six different freshly 
dissociated human glioblastoma tissues. Of 465 single cells analyzed, 35 were 
selected as CD31-positive and 164 were selected as αSMA-positive (Fig. S1). 
Indeed, FN, EDA+FN, and EDB+FN were preferentially expressed in CD31+ vs. 
CD31- cells (Fig. 1E, upper panels) and in αSMA+ vs. αSMA- cells (Fig. 1E, lower 
panels), suggesting that both endothelial cells and perivascular cells contribute to the 
expression of EDA+FN and EDB+FN in glioblastoma blood vessels. With around half 
of the CD31+ cells also showing αSMA expression on mRNA levels (Fig. S1), we 
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also confirmed that endothelial cells may express αSMA in glioblastoma (Huang et 
al., 2016). In line, investigating CD31+ cells isolated from freshly dissociated tumor 
tissues from four other patients, we confirmed expression of αSMA in this ex vivo 
model. Since it has been reported that EDA+FN controls αSMA expression in 
fibroblasts (Serini et al., 1998), we performed selective gene silencing, reaching more 
than 90% in all models for both targets (data not shown), of EDA+FN or EDB+FN in 
four CD31+ cell lines derived from human glioblastoma tissue (ZH-464, ZH-483-2, 
ZH-613, ZH-616). EDA+FN and EDB+FN gene silencing reduced αSMA mRNA 
levels in all the four cell lines (Fig. 1F), suggesting a role for EDA+FN and EDB+FN 
in the regulation of αSMA expression in glioblastoma-derived endothelial cells. 
Since TGF-β induces FN (Ignotz and Massague, 1986) and since alternative splicing 
of FN, including the generation of EDA+FN and EDB+FN, is mainly regulated by 
TGF-β in several cell types, we also considered the three TGF-β isoforms, TGF-β1, 
TGF-β2 and TGF-β3 in our single cell analysis of the six glioblastoma patients for a 
correlation analysis in the CD31+ and αSMA+ cell subpopulations. With regard to the 
CD31+ subpopulation, we observed a trend of positive correlation in the expression 
of TGF-β1 and FN (r2=0.13, p=3.5e-02), TGF-β1 and EDA+FN (r2=0.22, p=4.3e-03) 
and of TGF-β3 and FN (r2=0.12, p=3.8e-02) and EDB+FN (r2=0.14, p=2.5e-02) (Fig. 
2, upper panels). In the αSMA+ cell fraction, all TGF-β isoforms showed a significant, 
but overall less pronounced positive correlation with the expression of FN, EDA+FN, 
and EDB+FN (Fig. 2, lower panels). Of note, in both CD31+ and αSMA+ cells, we 
also observed a positive correlation in the expression of FN and of transforming-
growth factor β-induced (TGFBI) (Fig. 2), an extracellular matrix protein which is 
associated with malignancy and which is TGF-β-inducible (Gopal et al., 2017). 
Relevant proteins for TGF-β storage and activation in the ECM also include the latent 
TGF-β binding proteins (LTBP) with the isoforms LTBP1, LTBP2, LTBP3 and LTBP4 
(Robertson et al., 2015). Therefore we also included these targets into the analysis 
which revealed a significant positive correlation of LTBP1 and FN, EDA+FN, and 
EDB+FN, of LTPB2 and FN and EDA+FN, and of LTBP3 and FN in the CD31+ cell 
fraction (Fig. 2, upper panels). All LTBP molecules significantly positively correlated 
with FN, EDA+FN, and EDB+FN in the αSMA+ cell fraction, except for LTBP3 and 
EDB+FN (Fig. 2, lower panels).  
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TGF-β1, TGF-β2 and TGF-β3 induce FN, EDA+FN, and EDB+FN in endothelial 
cells. 
To investigate the potential regulation of EDA+FN and EDB+FN expression by TGF-
β isoforms in endothelial cells in vitro, we used human cerebral microvascular 
endothelial cells (hCMEC). Exposure to TGF-β1, TGF-β2 or TGF-β3 increased 
mRNA expression of total FN, EDA+FN, and EDB+FN, as wells as protein levels of 
soluble FN, EDA+FN and EDB+FN as measured in the conditioned culture media of 
hCMEC cells (Fig. 3A). We also measured the levels of FN incorporated in the 
insoluble extracellular matrix and found that the levels of insoluble total FN and 
EDA+FN were increased whereas the levels of insoluble EDB+FN were not 
significantly changed upon TGF-β treatment, suggesting that the EDB+FN isoform is 
mainly released into solution (Fig. S2). To explore the molecular mechanism by 
which TGF-β isoforms induce FN expression in hCMEC, we first used the TGF-βRI-
specific kinase activity inhibitor SD-208 (Uhl et al., 2004). SD-208 abolished the TGF-
β1-, TGF-β2- and TGF-β3-mediated induction of FN, EDA+FN, and EDB+FN on both 
mRNA and protein level (Fig. 3A), indicating that the process is TGF-βRI-dependent 
and equally valid for all three TGF-β isoforms. To further specify the signal 
transduction pathway downstream of the TGF- receptors, we first investigated the 
canonical, SMAD-dependent TGF-β signaling pathway. Gene silencing of SMAD4, 
with an efficacy on mRNA level of ~88% (data not shown), inhibited the TGF-β1- and 
TGF-β2-induced increase in FN, EDA+FN, and EDB+FN on mRNA and protein 
levels, indicating the involvement of the SMAD signaling pathway (Fig. 3B, data for 
TGF-1 not shown). Also, gene silencing of SMAD3, but not of SMAD2 (Fig. 3C, left 
panel), abolished the TGF-β1- and TGF-β2-dependent induction of FN, EDA+FN and 
EDB+FN expression (Fig. 3C, data for TGF-1 not shown). The efficacy of the gene 
silencing on mRNA level was ~90% and ~60% for SMAD2 and SMAD3, respectively, 
and SMAD2 and SMAD3 gene silencing was also verified on protein level at the time 
when the cells were treated with TGF-β (data not shown). Notably, gene silencing of 
SMAD3 reduced the relative fraction of FN molecules containing EDB by two-fold, 
whereas the relative fraction of FN molecules containing EDA remained unchanged 
(Fig. 3C, right panel), pointing towards a specific role for SMAD3 in the control of the 
splicing of the EDB domain. The inhibitory effect of SMAD3 gene silencing on TGF-
β1- and TGF-β2-mediated induction of FN, EDA+FN and EDB+FN also translated 
into reduced protein levels (Fig. 3C, central panels, data for TGF-β1 not shown). 
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Since a role for JNK in the TGF-β-dependent induction of FN expression has been 
reported in human fibrosarcoma cells (Hocevar et al., 1999) and in light of the known 
cross-talk between canonical/SMAD-dependent and non-canonical/SMAD-
independent TGF-β signaling pathways, we also explored the role for JNK in our 
model. The JNK-specific inhibitor SP600125 had only minor inhibitory effects on the 
TGF-β2-dependent induction of total FN or EDA+FN but abolished the TGF-β2-
dependent induction of EDB+FN on mRNA and protein levels (Fig. S3). These data 
suggest JNK signaling as potential additional pathway controlling EDB+FN splicing in 
hCMEC cells.  
To investigate this process in a model more closely reflecting the in vivo situation, we 
analyzed the effect of TGF-β1 and TGF-β2 on FN in human glioblastoma-derived 
CD31+ cells. TGF-β1 and TGF-β2 induced the expression of FN, EDA+FN and 
EDB+FN in the two patient-derived CD31+ cell lines ZH-459 (Fig. 4A) and ZH-613 
(Fig. 4B). In line with our results for hCMEC (Fig. 3), TGF-β2-induced expression of 
FN, EDA+FN and EDB+FN was TGF-βRI- (Fig. 4C) and SMAD3/SMAD4-dependent 
(Fig. 4D). In CD31+ cells derived from another glioblastoma patient (ZH-616), TGF-
β2 did not induce FN, EDA+FN, and EDB+FB, but gene silencing of SMAD3 and 
SMAD4 even reduced basal levels of EDA+FN and EDB+FN (Fig. 4E). 
 
EDA+FN and EDB+FN modulate TGF-β superfamily signaling in hCMEC. 
In endothelial cells, TGF-β may activate both the SMAD1,5,8- and SMAD2,3- 
dependent signal transduction pathways involving ALK1 and ALK5 respectively 
(Goumans et al., 2002). Further, FN and integrin α5β1 may control SMAD1,5,8 
phosphorylation by promoting the formation of ALK1/endoglin complexes (Tian et al., 
2012). To decipher the situation in hCMEC cells with very low levels of pSMAD2 in 
basal conditions, we first performed ALK1 and ALK5 gene silencing. ALK1 gene 
silencing affected neither the phosphorylation of SMAD1,5 nor that of SMAD2,3 in 
both basal conditions and upon TGF-β stimulation (Fig. S4A). Gene-specific silencing 
of ALK5 (Fig. S4A), treatment with the TGF-βRI-specific kinase activity inhibitor SD-
208 (Fig. S4B) or gene-specific silencing of TGF-βRII (Fig. S4C) inhibited the TGF-β-
induced increase in SMAD1,5 and SMAD2,3 phosphorylation levels and reduced 
basal pSMAD3 levels, without affecting basal pSMAD1,5 levels. This implies that in 
hCMEC TGF-β-induced SMAD1,2,3,5 phosphorylation is TGF-βRII- and ALK5-
dependent and that endogenous TGF-β rather controls basal pSMAD3 levels, 
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whereas basal pSMAD1,5 levels may be controlled by other members of the TGF-β 
superfamily such as BMP. With these data in mind, we further investigated the 
potential control of TGF-β superfamily signaling by EDA+FN and EDB+FN in 
endothelial cells by performing transient gene silencing of EDA+FN and EDB+FN in 
hCMEC, with EDA specific-knockdown also affecting the levels of total FN pointing 
towards the presence of EDA in the majority of the FN molecules (Fig. 5A, left panel). 
The levels of pSMAD1,5 were reduced in both siEDA+FN and siEDB+FN gene-
silenced cells. Cells with EDA+FN gene silencing showed also reduced levels of 
pSMAD3, whereas the levels of pSMAD2 were unaffected (Fig. 5A). To evaluate the 
mechanism of the reduction of pSMAD levels by EDA+FN and EDB+FN gene-
silencing, we analyzed the levels of TGF-β1 in the conditioned media of the 
respective cells. We did not look at the levels of the other TGF-β isoforms since 
hCMEC show low levels of TGF-β2 and undetectable levels of TGF-β3 (data not 
shown). TGF-β1 is synthesized as a proprotein (pro-TGF-β1, 55 kDa) and its 
processing results in the generation of two molecules, the pro-domain known as 
latency associated peptide (LAP, 37 kDa) and mature TGF-β1 (12.5 kDa) (Constam, 
2014). After pro-TGF-β processing, a covalent dimer of the LAP and a covalent dimer 
of mature TGF-β1 remain non-covalently associated forming the small latent complex 
(SLC, ~ 110 kDa). Both the SLC and the secreted unprocessed pro-TGF-β1 
covalently bind via LAP to molecules belonging to the LTBP family forming the large 
latent complex (LLC, ~ 270 kDa). In siEDA+FN cells-derived and to a less 
pronounced extent also in siEDB+FN cells-derived conditioned media, analyzed by 
immunoblot under reducing conditions, the levels of pro-TGF-β1 as well as LAP and 
mature TGF-β1 were reduced (Fig. 5B, left panel; the conditioned media of hCMEC 
with the gene silencing of TGF-β1 are shown to identify the correct bands). The 
analysis of the same conditioned media under non-reducing conditions revealed that 
the reduction in TGF-β1 levels in the conditioned media of the siEDA+FN and 
siEDB+FN cells went along with a reduction in the levels of TGF-β1/LLC (Fig. 5B, 
central panel). We also analyzed the respective lysate in order to detect intracellular 
TGF-β1 levels and found that upon EDA+FN and EDB+FN gene silencing the 
intracellular levels of pro-TGFβ1 and LAP were unchanged (Fig. 5B, right panel). In 
agreement, the mRNA levels of TGF-β1 were not significantly changed in siEDA+FN 
or siEDB+FN cells when compared to control cells (data not shown). Taken together 
this analysis differentiating TGF-1 levels in the lysates and supernatants suggests 
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that FN and oncofetal FN do not affect TGF-β1 protein secretion but rather control 
the levels of TGF-β1 available extracellularly. Since the gene silencing of EDA+FN 
also affected total levels of FN and EDB+FN levels (see Fig. 5A, left panel), we 
extended our analysis by a different approach to confirm the specific involvement of 
the EDA and EDB domains in the control of SMAD phosphorylation. This was based 
on the use of recombinant FN fragments including or excluding the EDA and EDB 
domains (Fig. 5C). Indeed, hCMEC treated with a recombinant FN fragment 
containing the EDB domain and adjacent FN type III domains 7, 8 and 9 (7-EDB-8-9) 
showed reduced levels of pSMAD1,5 compared with untreated cells or cells treated 
with the corresponding FN fragment lacking the EDB domain (7-8-9). The levels of 
pSMAD2 and 3 were unchanged (Fig. 5D). Treatment with the recombinant EDB 
domain alone (without the adjacent domains 7, 8 and 9) had only minor effects on the 
pSMAD1,5 levels, indicating the involvement of flanking domains in mediating the 
EDB effect. Compared to untreated cells or cells treated with the recombinant 
fragments including the two flanking EDA domains 11-12 and lacking EDA, hCMEC 
cells treated with the recombinant EDA domain alone showed decreased levels of 
pSMAD1,5 whereas the levels of pSMAD2 and pSMAD3 were unaffected. pSMAD1,5 
levels were reduced in cells treated with the FN fragment 11-12 to a lesser extent 
than in cells treated with the EDA domain alone (Fig. 5D). Upon stimulation with 
recombinant TGF-β2, both the FN fragments 7-EDB-8-9 and EDA inhibited the 
increase in the phosphorylation of SMAD1,5 and, to a lesser extent, of SMAD2,3 
when compared to untreated cells or cells treated with FN fragments lacking the EDA 
and EDB domains (Fig. 5E), confirming that both the EDA and the EDB domains of 
fibronectin are involved in the modulation of TGF-β superfamily signaling in hCMEC. 
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DISCUSSION 
The FN splice isoforms containing the EDA and EDB domains, EDA+FN and 
EDB+FN, are strongly expressed in the vasculature and the heart of the developing 
embryo (Astrof and Hynes, 2009). After completion of developmental processes, both 
EDA+FN and EDB+FN are down-regulated and are almost undetectable in mature 
adult blood vessels and tissues, except in tissues undergoing physiological 
remodeling and angiogenesis, like the uterus and the ovary. During pathological 
tissue remodeling, in chronically inflamed tissues and tumors, these oncofetal FN 
isoforms are re-expressed and accumulate around newly forming vessels (Astrof and 
Hynes, 2009). In particular, EDB+FN is considered a marker of angiogenesis since 
its expression in the adult blood vasculature is restricted to vessels undergoing neo-
angiogenesis (Castellani et al., 1994).  
Previous reports showed that FN is up-regulated in glioblastoma vasculature 
(Dieterich et al., 2012) and that in gliomas the percentage of vessels expressing 
EDB+FN correlates with tumor grade (Castellani et al., 2002). Here we show that in 
glioblastoma the expression of not only the isoform EDB+FN, but also the isoform 
EDA+FN is abundant and restricted to tumor vasculature (Fig. 1B). In addition, we 
show that both CD31+ and αSMA+ cells derived from freshly dissociated 
glioblastoma, representing endothelial cells and pericytes/VSMC, respectively, 
express FN, EDA+FN, and EDB+FN showing the contribution of both endothelial and 
perivascular cells to the production of EDA+FN/EDB+FN in glioblastoma blood 
vessels (Fig. 1C,E). Fibroblasts, which are characterized by αSMA expression, are 
rare cells in the brain. However, a subpopulation of cells showing properties of 
cancer-associated fibroblasts, expressing αSMA and localizing around blood vessels, 
has been isolated in glioblastoma (Clavreul et al., 2012). Thus, there may be a minor 
contribution of αSMA+ cells derived from fibroblasts-like cells in addition to the one of 
pericytes/VSMC in expressing (oncofetal) FN. Overall, as shown in Fig. 1D and as 
previously reported (Takeuchi et al., 2010), αSMA shows a vascular distribution 
pattern in glioblastoma, so that the vast majority of the cells included in the αSMA+ 
cell subpopulation is blood vessel-associated. Endothelial cells in glioblastoma may 
undergo endothelial-to-mesenchymal transition (End-MT) and express αSMA (Huang 
et al., 2016). In line, we observed that CD31+ cells derived from freshly dissociated 
human glioblastoma express αSMA ex vivo. In these cells, EDA+FN and EDB+FN 
gene silencing strongly reduced αSMA expression, suggesting a role for oncofetal FN 
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in promoting the expression of αSMA favoring the EndMT process in glioblastoma-
derived endothelial cells (Fig. 1F). Similarly, a role for EDA+FN in promoting the 
conversion of fibroblastic precursors into myofibroblasts expressing αSMA has been 
reported (Muro et al., 2008; Serini et al., 1998; White et al., 2008). 
Glioblastomas are characterized by high vascular density and vascular 
abnormalization with the typical formation of glomeruloid vascular structures (Wen 
and Kesari, 2008). All TGF-β isoforms and most abundantly TGF-β1 and TGF-β2 are 
expressed in glioblastoma (Frei et al., 2015), and they have been attributed a central 
role in both tumor angiogenesis and vessel remodeling. A direct role for TGF-β2 in 
regulating the phenotype of glioblastoma vessels, including the expression of 
components of the extracellular matrix, has been proposed. Indeed SMAD2/SMAD4 
and SMAD3/SMAD4 complexes localize mainly to the vascular and perivascular 
areas in glioblastoma (Dieterich et al., 2012). TGF-β induces FN in several cell types 
(Ignotz and Massague, 1986) and is one of the best characterized modulators of the 
alternative splicing affecting the EDA and EDB domains (Balza et al., 1988; Borsi et 
al., 1990; Viedt et al., 1995). Here we show a trend of positive correlation in the 
expression of the three TGF-β isoforms and EDA+FN and EDB+FN in CD31+ cells 
derived from freshly dissociated human glioblastoma (Fig. 2). Also, we observed 
positive correlations in the expression of all TGF-β isoforms and FN, EDA+FN and 
EDB+FN in the αSMA+ cells fraction (Fig. 2). Notably, our studies reveal that TGF-
β1, TGF-β2 and TGF-β3 induce FN, EDA+FN, and EDB+FN in hCMEC cells (Fig. 3). 
Here, induction of FN, EDA+FN, and EDB+FN by TGF-β involves the SMAD-
dependent/canonical TGF-β signaling pathway and specifically SMAD3 (Fig. 3). In 
vitro experiments performed in CD31+ cells derived from freshly dissociated human 
glioblastoma revealed inter-patient variability, since TGF-β induced FN, EDA+FN and 
EDB+FN only in two out of the three cell line models derived from these patients (Fig. 
4). We did not observe an inducibility of FN and oncofetal FN by TGF-β in the third 
primary cell line tested (ZH-616), but endogenous expression levels of oncofetal FN 
were dependent on SMAD3 and SMAD4. Thus, our data support a role for TGF-
/SMAD3/SMAD4-signaling in (oncofetal) FN expression in endothelial cells (Figs 3, 
4). 
In both CD31+ and αSMA+ cells, we also observed a positive correlation in the 
expression of TGFBI and FN, EDA+FN and EDB+FN (Fig. 2). TGFBI is an 
extracellular matrix glycoprotein, interacting with FN (Billings et al., 2002), induced by 
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TGF-β and previously reported to be up-regulated in glioblastoma vasculature 
(Mustafa et al., 2012). Strong positive correlations in the expression of TGFBI and FN 
have been reported in other contexts such as ovarian cancer (Ahmed et al., 2007). In 
addition, we observed positive correlations in the expression of FN and LTBP 
molecules (Fig. 2), the last ones being ECM molecules that bind to FN and that play 
a central role in the control of TGF-β latency and activation (Robertson et al., 2015). 
Overall, the positive correlations in the expression of the ECM-localized TGF-β target 
genes FN and TGFBI, as well as in the expression of ECM components involved in 
TGF-β storage and activation i.e. FN and LTBP, suggest a coordinated expression in 
the major ECM glycoproteins associated with TGF-β activity (Gopal et al., 2017) in 
glioblastoma vasculature. 
The potential role played by oncofetal FN in neo-angiogenesis and vascular 
morphogenesis is still unclear. Double null mice for EDA and EDB domains die at 
embryonic stage with several vascular defects (Astrof et al., 2007). By contrast, 
single knockout mice for EDA and EDB containing FN isoforms are vital, show 
normal vasculogenesis (Fukuda et al., 2002; Muro et al., 2008) and normal 
physiological and tumor angiogenesis (Astrof et al., 2004). Since EDA/EDB null mice 
have phenotypical similarities with knockout mice for different growth factors 
including TGF-β1 (Kulkarni et al., 1995), a role for the EDA and EDB domains of FN 
in regulating TGF-β signaling has been postulated (Astrof and Hynes, 2009). In the 
present work, we demonstrate that gene silencing of EDA+FN and EDB+FN in 
hCMEC reduces the levels of phosphorylated SMAD1,5, in addition pSMAD3 levels 
were reduced upon EDA+FN-gene silencing as well (Fig. 5A). Interestingly, gene-
silencing of EDB+FN in hCMEC and to a larger extent gene silencing of EDA+FN 
reduced levels of TGF-β1 in the conditioned media of these cells (Fig. 5B). This 
explains the reduction in pSMAD3 levels and suggests a role for FN and its splice 
variants in the control of TGF-β signaling in the ECM by affecting TGF-β 
latency/activation. Also, treatment of hCMEC with recombinant fragments of FN 
including the EDA and EDB domains reduced SMAD1,5 phosphorylation on both 
basal levels and upon TGF-β2 treatment when compared to untreated cells or cells 
treated with the FN fragments lacking the EDA and EDB domains (Fig. 5D,E). The 
same FN fragments also attenuated the induction of pSMAD2,3 upon TGF-β2 
treatment. Overall these data suggest that the EDA and EDB domains of FN 
modulate the TGF-β superfamily signaling in hCMEC. Similarly, in fibroblasts a role 
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for EDA+FN in controlling TGF-β activation has been reported (Muro et al., 2008; 
Serini et al., 1998; White et al., 2008).  
In summary, we show that EDA+FN and EDB+FN are abundantly expressed in 
glioblastoma vasculature and that both endothelial cells and pericytes/SVMC 
contribute to the expression of oncofetal FN in glioblastoma. In both CD31+ and 
αSMA+ cells TGF-β expression correlates with EDA+FN and EDB+FN expression. 
All TGF-β isoforms induce FN, EDA+FN, and EDB+FN in hCMEC and CD31+ cells 
derived from human glioblastoma tissues involving SMAD3/SMAD4. In turn, EDA+FN 
and EDB+FN modulate TGF-β superfamily signaling mainly affecting the SMAD1,5 
signaling branch which also depends on other TGF-β superfamily members than the 
isoforms TGF-β1, TGF-β2 and TGF-β3. Since TGF-β superfamily ligands play a 
central role in vasculogenesis and angiogenesis, further studies are needed to 
deepen our knowledge on this new mode of regulation of TGF-β superfamily 
signaling in neo-vessels involving oncofetal FN.  
 
MATERIAL AND METHODS 
 
Real-time PCR (RT-PCR) 
RT-PCR was performed using the primers reported in table S1. mRNA levels were 
determined by using the ΔCT method and ARF1 as housekeeping gene. 
 
Single-cell quantitative real-time polymerase chain reaction (qRT-PCR) 
Glioblastoma tissues obtained from surgery were immediately dissociated using a 
papain-based dissociation system (Worthington, Lakewood, NJ, USA). Leukocytes 
were depleted using anti-human CD45 microbeads (Milteny Biotech, Bergisch 
Gladbach, Germany). Single-cell qRT-PCR gene expression profiling was performed 
using the C1 Single-Cell Autoprep and BioMark HD instruments (Fluidigm, South San 
Francisco, CA, USA). Cells were captured on a C1 Single-Cell Preamp IFC (10–
17 μm) using the Fluidigm C1 and capture efficiency was evaluated under an 
inverted microscope to identify empty sites, sites with debris and multiple cells to 
exclude them from the final analysis. Preamplified cDNA was generated using the 
Single Cells-to-CT Kit (Life Technologies, Carlsbad, CA, USA), pooled qPCR primers 
(Table S1) and Fluidigm STA reagents. Preamplified cDNA was then used for high-
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throughput qPCR measurement of each amplicon using the BioMark HD system with 
IFC Controller HX (Fluidigm) and 2X SsoFast EvaGreen Supermix with Low ROX 
(Bio-Rad, Hercules, CA, USA). Single-cell expression data were collected using the 
Fluidigm Data Collection software. Quality controls included cDNAs derived from a 
whole glioblastoma tumor before and after CD45+ depletion and the qPCR Human 
Reference cDNA, random-primed (Clontech, Mountain View, CA, USA). For all 
tumors tested runs were performed successfully. All primers used were tested for 
amplification efficiency of at least 90% by generating standard curves for each gene. 
Data was processed via removal of cells with low overall expression values, 
identification of limits of detection for each analyzed gene and cell-to-cell median 
normalization as described previously (Livak et al., 2013). Informed consent was 
obtained from all patients and the analysis was performed according to the guidelines 
of the local ethics committees (Kantonale Ethikkommission Zürich, Switzerland, KEK-
ZH-Nr./BASCE-Nr. 2016-00456). 
 
Enzyme-linked immunosorbent assay 
For the detection of soluble FN, EDA+FN and EDB+FN, BRAND Immunograde 96 
well plates (Sigma-Aldrich, St. Louis, MO, USA) were coated with 20 µg/ml gelatin in 
PBS overnight at room temperature, washed with PBS, blocked with 2% bovine 
serum albumin (BSA) in PBS and then incubated with the conditioned culture media 
of cells cultured for 72. The conditioned media were tested at different dilutions in 2% 
BSA in order to make sure that the resulting readings were in the linear range. FN, 
EDA+FN, and EDB+FN were detected by using the IST-5 (Klein et al., 2003), IST-9 
(Borsi et al., 1987) and C6 (Balza et al., 2009) antibodies, respectively, at the final 
concentration of 2 µg/ml in 2% BSA in PBS. For the detection of insoluble FN, 
EDA+FN and EDB+FN cells cultured for 72 h in 96 well plate were fixed with 
methanol, blocked with 2% BSA in PBS and incubated with 0.5 µg/ml IST5 or 2 µg/ml 
IST9 or C6. The HRP goat anti-mouse IgG (minimal cross-reactivity) antibody 
(405306, lot #B167518, BioLegend, San Diego, CA, USA) was used as secondary 
antibody. 3,3’, 5,5’ tetramethylbenzidine (TMB) (BD Bioscience, San Jose, CA, USA) 
was used as a reaction substrate. Data for soluble FN, EDA+FN and EDB+FN are 
expressed as the values of absorbance at 450 nm divided by the protein 
concentration as determined in the undiluted cell conditioned media by Bradford 
Assay (Bio-Rad). In case of insoluble FN, cells seeded in a second 96 well plate and 
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subjected to the same treatments for 72 h, were incubated for 3 h with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). After cell lysis the 
absorbance at 540 nm was measured and used to normalize the ELISA data.  
 
Immunohistochemistry 
For immunohistochemical analysis of FN and CD31, methanol-fixed 5 µm cryostat 
sections of ten human glioblastoma and of four human normal brain tissues derived 
from patients with epilepsy were used. The analysis was performed according to the 
guidelines of the local ethics committees (Kantonale Ethikkommission Zürich, 
Switzerland, KEK-ZH-Nr./BASCE-Nr. 2016-00456). For the staining of fibronectins 
sections were treated with the primary antibodies IST-5, IST-9 and C6 at the final 
concentration of 2 µg/ml, the peroxidase mouse IgG Vectastain ABC kit (PK-4002, 
Vector Laboratories, Burlingame, CA, USA) and the DAB substrate (Peroxidase 
blocking, Dako-Agilent, Santa Clara, CA, USA). CD31+ positive cells were stained 
using the anti CD31+ monoclonal antibody clone JC70A (M0823, Lot#00063340, 
Dako, Glostrup, Denmark) diluted 1:40, the peroxidase mouse IgG Vectastain ABC 
kit (Vector Laboratories) and the DAB substrate (Dako-Agilent). For the αSMA IHC 
analysis, 5 µm formalin-fixed paraffin-embedded sections derived from two out of the 
six glioblastoma tissues employed also for the single-cell RT-PCR were used. Heat-
induced epitope retrieval was performed in 10 mM Tris buffer, 1 mM EDTA, pH 9.0. 
Tissue sections were then treated with the anti αSMA monoclonal antibody clone 1A4 
(A5228, batch 056M4828V, Sigma) diluted 1:50, the Histofine simple stain MAX PO 
(M) universal immuno-peroxidase polymer anti-mouse (414132F, Nichirei 
Biosciences, Tokyo, Japan) and the DAB substrate (Dako-Agilent). Serial section 
were stained for CD31 as above described after heat-induced epitope retrieval in 0.1 
M citrate buffer pH 6.0. Images were acquired using an Axio Scope.A1 microscope 
equipped with an AxioCam MRc camera and the AxioVision LE64 program (Carl 
Zeiss, Oberkochen, Germany). 
 
Immunoblot 
Denatured and reduced (with 5% β-mercaptoethanol) whole cell lysates or denatured 
concentrated conditioned media under reducing or non-reducing conditions were 
separated by polyacrylamide gels and transferred to nitrocellulose membranes 
(Amersham/Ge Healthcare Life Science, Arlington Heights, IL, USA). Membranes 
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were blocked with 5% skimmed milk or serum bovine albumin (ApplChem, 
Darmstadt, Germany) and treated with the following primary antibodies: IST-4 
(Sekiguchi et al., 1985), IST-9 and C6 (see above) antibodies to fibronectin used at 
the final concentration of 5 µg/ml; the antibodies specific for SMAD1 (9743, 
ref:01/2012), phosphorylated SMAD1/5 (pSmad1/5(Ser463/465)) (9516, ref.08/2015), 
SMAD2 (3122, ref:05/2015), phosphorylated SMAD2 (pSMAD2 (Ser465/467)) (3108, 
ref: 04/2016), SMAD3 (9513, ref: 07/2014), and SMAD4 (9515, ref:08/2013) from Cell 
Signaling Technology (Danvers, MA, USA), used diluted 1:1000 except for anti-
pSMAD2 which was diluted 1:500; anti-phosphorylated SMAD3 (ab52903, 
lot#GR128879-24, Abcam, Cambridge, UK) diluted 1:1000; anti-human LAP/TGF-β1 
(AF-246-NA, lot#EF0212101, R&D Systems, Minneapolis, MN, USA) diluted 1:2000, 
anti-TGF-β1 (G122A, lot#0000051912, Promega, Madison, WI, USA) diluted 1:1000, 
anti-GAPDH (EB07069, lot#C2, Everest Biotech, Ramona, CA, USA) at the final 
concentration of 0.2 µg/ml. Secondary antibodies used were HRP-coupled goat anti-
rabbit (sc-2004, lot #B2216) or donkey anti-goat (sc-2033, lot #A2914) (Santa Cruz 
Biotechnology, Dallas, TX, USA) or sheep anti-mouse antibodies (NA931V, lot 
#9997907, Ge Healthcare UK Limited, Amersham, UK), diluted 1:5000. Protein 
bands were visualized with horseradish peroxidase (HRP)-coupled secondary 
antibodies followed by enhanced chemiluminescence (Pierce/Thermo Fisher, 
Madison, WI, USA). 
 
Cell culture 
Human cerebral microvascular endothelial cells (hCMEC-D3) were kindly provided by 
P.C. Couraud (Paris, France). The human glioblastoma-derived CD31+ cell line ZH-
459, ZH-464, and ZH-483-2 have been reported (Krishnan et al., 2015). The human 
glioblastoma-derived CD31+ cell lines ZH-613 and ZH-616 were prepared as 
described (Krishnan et al., 2015). Endothelial cells were cultured in EBM-2 medium 
(CC-3156, Lonza, Walkersville, MD), containing 0.1 M HEPES (Gibco), 1% v/v CD 
lipid concentrate (Gibco) and endothelial growth supplements (EGM-2-CC4176, 
Lonza). HCMEC-D3 were negatively tested for contamination with mycoplasma. 
Glioblastoma-derived cell lines were not tested for contamination and were not 
recently authenticated because they were used at low passage number. Informed 
consent was obtained from all patients. 
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Reagents 
Transient gene silencing was performed by using the Lipofectamine RNAiMAX 
reagent (Invitrogen/Life Technologies) and the following siRNA provided by 
Dharmacon (Lafayette, CO, USA): ON-TARGETplus, siRNA SMART pools specific 
for SMAD2 (L-003561-00), SMAD3 (L-020067-00), SMAD4 (L-003902-00), TGF-βRII 
(L-003930–00), ALK1 (L-005302–02), ALK5 (L-003929–00), TGF-β1 (L-012562-00) 
and non-targeting control (D-001810-10) at a final concentration of 100 nM. For 
EDA+FN and EDB+FN the following siRNA provided by Dharmacon and used at the 
final concentration of 10nM were used: 1) EDA+FN: pool of siEDA1 5'- 
GGTTCTGAGTACACAGTCA-3' and siEDA2 5'- GGTTCTGAGTACACAGTCA 
3'; 2) EDB+FN: a pool of four siRNA previously described (Khan et al., 2005). 
Cells were treated using the following reagents in EBM-2 medium without 
supplements: 5 ng/ml TGF-β1, TGF-β2 or TGF-β3 (R&D Systems, Minneapolis, MN, 
USA), 1 µM SD-208 (Scios, Fremont, CA, USA) and 10 µM SP600125 (Sigma-
Aldrich). The human fibronectin recombinant fragments used in this study were 
previously described (Carnemolla et al., 1996). 
 
Statistical analysis 
All experiments were performed at least twice and in triplicates. Statistical analysis 
for the scRT-PCR data was performed in R using the package ggplot2. All other 
statistical analysis was performed by using the GraphPad Prism 5 program. Data are 
shown as the mean ± the standard deviation (SD). The statistical significance of the 
RT-PCR and ELISA data was determined by performing one-way ANOVA followed 
by Tukey’s post hoc test at 95% confidence interval (CI). 
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
ABBREVIATIONS 
Transforming growth factor (TGF)-β; fibronectin (FN); extra-domain A (EDA); extra-
domain B (EDB); extracellular matrix (ECM); activin-like kinase (ALK); bone 
morphogenetic proteins (BMP); alpha-smooth muscle actin (αSMA); vascular smooth 
muscle cells (VSMC); transforming growth factor-β induced (TGFBI); latent TGF-β 
binding protein (LTBP); latency-associated peptide (LAP); small latent complex 
(SLC); large latent complex (LLC) ; human cerebral microvascular endothelial cells 
(hCMEC); single-cell real-time polymerase chain reaction (scRT-PCR). 
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Figures 
 
 
 
Figure 1. EDA+FN and EDB+FN are expressed in glioblastoma blood vessels. 
A. Schematic representation of the modular structure of FN. The target regions of the 
monoclonal antibodies specific for the FN type III repeat 5 (IST-4 and IST-5), 
EDA+FN (IST-9) and EDB+FN (C6) are indicated. B. CD31, total FN, EDA+FN and 
EDB+FN were detected immunohistochemically in frozen glioblastoma sections and 
in frozen normal brain sections obtained from epilepsy surgery. Representative 
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
photomicrographs of two glioblastoma patients and one of the patients suffering from 
epilepsy are shown, bars indicate 50 µm. C. Total FN, EDA+FN and EDB+FN mRNA 
levels were determined in CD31+ vs. CD31- cells isolated from freshly dissociated 
glioblastoma tissues by RT-PCR. The “ZH” headings refer to codes for individual 
patients. Data are mean of technical triplicates ± SD. D. CD31 and αSMA were 
immunohistochemically detected in paraffin-embedded glioblastoma sections. Bars 
indicate 100 µm. E. Normalized relative gene expression on a log2 scale of FN, 
EDA+FN, and EDB+FN in individual cells derived from freshly dissociated human 
glioblastoma. Data from 6 individual tumors were pooled and cells were divided into 
CD31+ (N=35) and CD31- (N=430) (upper panels) and in αSMA+ (N=164) and 
αSMA- (N=301) (lower panels) subpopulations. Grey dots are all the actual data 
points. Boxes depict the median and interquartile ranges, whiskers extend to the 
largest value no further than 1.5-fold interquartile ranges from the hinge. In case of 
the CD31- and αSMA- cells the median values for EDB+FN are at 0. Two-sided t-test 
and Bonferroni adjustment for multiple testing were performed to compare gene 
expression in CD31+ vs. CD31- or αSMA+ vs. αSMA- cells. F. αSMA mRNA levels 
were determined by RT-PCR in the indicated CD31+ sub-cell lines upon specific 
gene silencing of EDA+FN, EDB+FN or non-targeting control. The “ZH” headings 
refer to codes for individual patients. Data are expressed as mean of technical 
triplicates ± SD (*p<.05, **p<.01, ***p<.001 one-way ANOVA followed by Tukey’s 
post hoc test 95% CI). 
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Figure 2. Positive correlations between the expression of TGF-β, TGF-β-
induced (TGFBI), latent TGF-β binding proteins (LTBP) and of EDA+FN or 
EDB+FN on a single cell level in CD31+ and αSMA+ cells derived from human 
glioblastoma. Single cell RT-PCR in CD31+ (upper panels) and αSMA+ (lower 
panels) cells derived from freshly dissociated human glioblastoma (N=6). Data from 
the 6 individual patients were pooled. Dots are all the actual data points. X-axis: 
normalized relative log2 expression values of TGF-β1, TGF-β2, TGF-β3, TGFBI, 
LTBP1, LTBP2, LTBP3 and LTBP4; y-axis: normalized relative log2 expression 
values of FN, EDA+FN and EDB+FN. Correlations are indicated by slopes of blue 
lines. p-values are significance of the slope coefficient for each graph, Benjamini-
Hochberg adjusted. 
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Figure 3. TGF-β1, TGF-β2 and TGF-β3 induce EDA+FN and EDB+FN expression 
in hCMEC in a TGF-βRI- and SMAD4/SMAD3-dependent manner. In all 
experiments FN, EDA+FN and EDB+FN levels were determined on mRNA level 48 h 
post TGF-β treatment by RT-PCR and on protein level in the conditioned media 72 h 
post TGF-β1, TGF-β2 or TGF-β3 treatment by ELISA. A. FN, EDA+FN and EDB+FN 
mRNA (left panel) and protein levels (other panels) in hCMEC cells incubated with 1 
µM SD-208 or DMSO as solvent control for 1 h and then treated with 5 ng/ml TGF-
β1, TGF-β2 or TGF-β3 (* DMSO + TGF-β1 or TGF-β2 or TGF-β3 vs. DMSO; # 
DMSO + TGFβ1 or TGFβ2 or TGF-β3 vs. SD-208 + TGF-β1 or TGF-β2 or TGF-β3). 
B. FN, EDA+FN and EDB+FN mRNA (left panel) and protein (other panels) levels in 
hCMEC transfected with siRNA targeting SMAD4 or non-targeting control and treated 
with 5 ng/ml TGF-β2 24 h post-transfection (ELISA data: * siCTR + TGF-β2 vs. 
siCTR; # siCTR + TGFβ2 vs. siSMAD4 + TGF-β2). C. FN, EDA+FN and EDB+FN 
mRNA levels (left panel) in hCMEC transfected with siRNA targeting SMAD2, 
SMAD3 or non-targeting control and treated with 5 ng/ml TGF-β2 24 h post-
transfection. FN, EDA+FN and EDB+FN protein levels in hCMEC transfected with 
siRNA targeting SMAD3 or non-targeting control and treated with 5 ng/ml TGF-β2 24 
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h post-transfection (central panels). The fold change in the fraction of FN molecules 
containing the EDA domain or EDB domain, using the RT-PCR data reported on the 
left panel, is indicated (right panel) (ELISA data:* siCTR + TGFβ2 vs. siCTR; # siCTR 
+ TGFβ2 vs. siSMAD3 + TGFβ2). All experiments were repeated at least twice. Data 
are mean of triplicates (technical for RT-PCR data and biological for ELISA data) ± 
SD (*/#p<.05, **/##p<.01, ***/###p<.001 one-way ANOVA followed by Tukey’s post hoc 
test 95% CI). 
Jo
ur
na
l o
f C
el
l S
ci
en
ce
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
  
Figure 4. TGF-β1 and TGF-β2 induce EDA+FN and EDB+FN expression in 
CD31+ cells derived from glioblastoma in a TGF-βRI- and SMAD4/SMAD3-
dependent manner. A-B. FN, EDA+FN and EDB+FN mRNA levels in ZH-459 
CD31+ (A) and in ZH-613 CD31+ cells (B) treated with 5 ng/ml TGF-β1 or TGF-β2 for 
48 h (* TGF-β1 or TGF-β2 vs. untreated). C. FN, EDA+FN and EDB+FN mRNA 
levels in ZH-613 CD31+ cells incubated for 1 h with 1 µM SD-208 or DMSO as 
solvent control and then treated with 5 ng/ml TGF-β2 for 48 h (* DMSO + TGF-β2 vs. 
all other samples). D-E. FN, EDA+FN and EDB+FN mRNA levels in ZH-613 CD31+ 
(D) and ZH-616 CD31+ (E) cells transfected with siRNA targeting SMAD3, SMAD4 or 
non-targeting control and then treated with 5 ng/ml TGF-β2 24 h post-transfection for 
48 h (in D, * siCTR + TGF-β2 vs. all other samples). The “ZH” headings refer to 
codes for individual patients. Data are mean of technical triplicates ± SD (**p<.01, 
***p<.001 one-way ANOVA followed by Tukey’s post hoc test 95% CI). 
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Figure 5. The EDA and EDB domains of fibronectin control TGF-β superfamily 
signaling in hCMEC. A. hCMEC were transfected with siRNA targeting the EDA or 
EDB domains of FN or non-targeting control siRNA (siCTR). At 24 h post transfection 
cells were transferred to a new dish and cultured in full medium. At 48 h post 
transfection cells were put in serum-free medium for 48 h. Concentrated conditioned 
culture media were analyzed for the levels of total FN, EDA+FN, and EDB+FN (left 
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panel). The levels of phosphorylated and total SMAD1,5, SMAD2 and SMAD3 were 
analyzed in cell lysates. The densitometry analysis of the immunoblot is indicated. B. 
The levels of pro-TGF-β1 (expected molecular weight of ~ 55 kDa), LAP/TGF-β1 
(expected molecular weight of ~ 37 kDa), and mature TGF-β1 (expected molecular 
weight of ~ 12.5 kDa) were determined in the conditioned media of siCTR, 
siEDA+FN, siEDB+FN cells and in siTGF-β1 and the respective control cells under 
reducing conditions by immunoblot (left panel). The TGF-β1/large latent complex (~ 
270 kDa), dimeric pro-TGF-β1 (~ 110 kDa) and dimeric LAP/TGF-β1 (~ 80 kDa) were 
detected in the same conditioned media analyzed under non-reducing conditions 
(central panel). Equal total protein loading was confirmed by red ponceau staining. 
Pro-TGF-β1, LAP/TGF-β1 and GAPDH were detected in the respective cell lysates 
analyzed under reducing conditions (right panel). C. Recombinant fragments of the 
FN molecule adjacent to the EDA and EDB domains including and excluding the 
extra-domains A and B used in this study. D. HCMEC were treated with the indicated 
FN recombinant fragments at 1 µM for 48 h. Levels of phosphorylated and total 
SMAD1,5, SMAD2 and SMAD3 were determined in cell lysates by immunoblot. E. 
HCMEC were treated with 1 µM FN recombinant fragments for 48 h and then 
exposed to 5 ng/ml TGF-β2 for 30 min. Levels of phosphorylated and total SMAD1,5, 
SMAD2 and SMAD3 were detected in cell lysates by immunoblot.  
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Fig. S1. Distribution of CD31 and αSMA expression in cells derived from
freshly dissociated human glioblastoma. Single cell RT-PCR in cells derived
from freshly dissociated human glioblastoma (N=6). X-axis: normalized relative
log2 expression value of CD31, y-axis: normalized relative log2 expression value
of αSMA.
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Fig. S2. Increased levels of insoluble total FN and EDA+FN in hCMEC treated with TGF-β1, TGF-β2 
and TGF-β3. HCMEC were seeded at 2000 cells/well in 96-well plate. After 24 h cells were pre-incubated 
with 1 µM SD-208 or DMSO control for 1 h. Cells were then treated with 5 ng/ml TGF-β1, TGF-β2 or TGF-
β3 for 72 h. Cells were then fixed and insoluble total FN, EDA+FN and EDB+FN were analyzed by ELISA. 
Another 96 well plate treated in the same manner was used for MTT assay 72 h post treatment. Data are 
expressed as the absorbance at 450 nm (ELISA assay) normalized by the absorbance at 540 nm (MTT 
assay). (* DMSO + TGF-β1 or TGF-β2 or TGF-β3 vs. DMSO; # DMSO + TGFβ1 or TGFβ2 or TGF-β3 vs. 
SD-208 + TGF-β1 or TGF-β2 or TGF-β3). Experiments were repeated three times. Data are mean of 
biological triplicates ± SD (*/#p<.05, **/##p<.01, ***/###p<.001 one-way ANOVA followed by Tukey’s post hoc 
test 95% CI).
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Fig. S3. JNK controls EDB+FN expression in hCMEC. FN, EDA+FN and EDB+FN mRNA (left panel) and 
protein levels (other panels) in hCMEC pre-incubated with 10 µM SP600125 for 2 h and then treated with 5 ng/ml 
TGF-β2 for 48 h (RNA data) or 72 h (protein data) (ELISA data: * DMSO + TGFβ2 vs. DMSO; # DMSO + TGFβ2 
vs. SP600125 + TGFβ2). Media were tested at different dilutions and the data are shown as the values of 
absorbance at 450 nm divided by the protein concentration as measured in undiluted media (1:1). Data are mean 
of triplicates (technical for RT-PCR data and biological for ELISA data) ± SD (*/#p<.05, **/##p<.01, ***/###p<.001 
one-way ANOVA followed by Tukey’s post hoc test 95% CI).
J. Cell Sci. 130: doi:10.1242/jcs.209619: Supplementary information
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
S
c
i
e
n
c
e
 
•
 
S
u
p
p
l
e
m
e
n
t
a
r
y
 
i
n
f
o
r
m
a
t
i
o
n
50
50
35
kDa
50
50
35
kDa
50
50
35
kDa
pSMAD1,5
GAPDH
SMAD1
pSMAD2
GAPDH
SMAD2
pSMAD3
GAPDH
SMAD3
A
TGF-β2     - - - +     +      +   - - - +      +      +    - - - +       +      +
B
TGF-β2     - - +     +  - - +      +   - - +      + 
pSMAD2
GAPDH
SMAD2
50
50
35
kDa
pSMAD1,5
GAPDH
SMAD1
50
50
35
kDa
pSMAD3
GAPDH
SMAD3
50
50
35
kDa
C
TGF-β2     - - +     +     - - +      + - - +      + 
pSMAD2
GAPDH
SMAD2
50
50
35
kDa
pSMAD3
GAPDH
SMAD3
50
50
35
kDa
pSMAD1,5
GAPDH
SMAD1
50
50
35
kDa
Fig. S4. TGF-β-induced SMAD phosphorylation is TGF-βRII- and ALK5-dependent in hCMEC. A. HCMEC
were transfected with siCTR or siRNA targeting ALK1 or ALK5. At 24 h post transfection cells were placed in serum-
free media for additional 24 h and then treated with 5 ng/ml TGF-β2 for 30 min. Total and phosphorylated SMAD
were analyzed in cell lysates. B. HCMEC were serum starved for 24 h, pre-incubated with 1 µM SD-208 or DMSO
as solvent control for 1 h and exposed to 5 ng/ml TGF-β2 for 30 min. C. HCMEC were transfected with siRNA
targeting TGF-βRII or siCTR. At 24 h post-transfection cells were placed in serum-free media for additional 24 h and
then treated with 5 ng/ml TGF-β2 for 30 min.
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Primer name Primer sequence 
FN fwd 5'-TACACTGGGAACACTTACCG-3' 
FN rev 5'-CCAATCTTGTAGGACTGACC-3’ 
EDA+FN fwd 5'-GGAGAGAGTCAGCCTCTGGTTCAG-3' 
EDA+FN rev 5’-TCTGCAGTGTCTTCTTCACC-3’ 
EDB+FN fwd 5'-TCAAGGATGACAAGGAAAGTG-3' 
EDB+FN rev 5'-AATAATGGTGGAAGAGTTTAGC-3' 
SMAD2 fwd 5'-GCACTTGCTCTGAAATTTGGGC-3' 
SMAD2 rev 5’-GACGACCATCAAGAGACCTGG-3’ 
SMAD3 fwd 5'-GCCTGTGCTGGAACATCATC-3' 
SMAD3 rev 5'-TTGCCCTCATGTGTGCTCTT-3’ 
SMAD4 fwd 5'-GGTTCCTTCAAGCTGCCCTA-3' 
SMAD4 rev 5'-ATGTGCAACCTTGCTCTCTCA-3’ 
TGF-β1 fwd 5'-GCCCTGGACACCAACTATTG-3’ 
TGF-β1 rev 5’-CGTGTCCAGGCTCCAAATG-3’ 
TGF-β2 fwd 5'-AAGCTTACACTGTCCCTGCTGC-3' 
TGF-β2 rev 5'-TGTGGAGGTGCCATCAATACCT-3' 
TGF-β3 fwd 5’-TCAGCCTCTCTCTGTCCACTT-3’ 
TGF-β3 rev 5’-CATCACCGTTGGCTCAGGG-3’ 
TGFBI fwd 5’-AAATCTGTGGCAAATCAACAGTCAT-3’ 
TGFBI rev 5’-TCCCAGGGTCTCGTAAAGGT-3’ 
LTBP1 fwd 5’-TACTTCATCCAAGACCGTTTTC-3’ 
LTBP1 rev 5’-AGGTCATCTTGGCCGTATCC-3’ 
LTBP2 fwd 5’-TTGACATAGACGAGTGCGCCA-3’ 
LTBP2 rev 5’-CACATACCGCCAGCATAAGCT-3’ 
LTBP3 fwd 5’-TTGTGAGGAGGTGGAGCAGC-3’ 
LTBP3 rev 5’-CGCAGAACACTGTGTCATCGA-3’ 
LTBP4 fwd 5’-AAGCTATGCTGGTTCCCTGG-3’ 
LTBP4 rev 5’-CGGCCTCATCACACTCGTTG-3’ 
CD31 fwd 5’-TTTGGACCAAGCAGAAGGCT-3’ 
CD31 rev 5’-TTGGCCGCAATGATCAAGAGA-3’ 
αSMA fwd  5’-GAGCGTGGCTATTCCTTCGTTA-3’ 
αSMA rev 5’-CCATCAGGCAACTCGTAACTCT-3’ 
ARF1 fwd 5'-GACCACGATCCTCTACAAGC-3' 
ARF1 rev 5’-TCCCACACAGTGAAGCTG-3’ 
 
Table S1. Sequences of the primers used in the study. 
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